RA
CRSP icon

RFG Advisory’s CRISPR Therapeutics CRSP Stock Holding History

RFG Advisory’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,289
Closed -$209K – 425
2021
Q2 		$209K Buy
+1,289
New +$157K 0.02% 420
2021
Q1 		– Sell
-3,384
Closed -$656K – 435
2020
Q4 		$656K Sell
3,384
-510
-13% -$60.3K 0.09% 199
2020
Q3 		$326K Buy
3,894
+886
+29% +$78.6K 0.05% 295
2020
Q2 		$221K Buy
+3,008
New +$176K 0.03% 348

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

RFG Advisory's CRSP Position: Q3 2021 in Review

RFG Advisory sold out of CRISPR Therapeutics (CRSP) in Q3 2021, closing a stake of 1,289 shares — an estimated $209K sold.

RFG Advisory first reported a position in CRSP in Q2 2020 and held it in 4 quarters. The position peaked at $656K in Q4 2020. 473 funds tracked by Wall St. Rank hold CRSP as of Q3 2021.

  • RFG Advisory reported no remaining CRISPR Therapeutics position as of Q3 2021 after selling out during the quarter.
  • RFG Advisory sold 1,289 CRISPR Therapeutics shares in Q3 2021, an estimated $209K.
  • RFG Advisory first reported a position in CRISPR Therapeutics in Q2 2020 and held it in 4 quarters.
  • RFG Advisory's CRISPR Therapeutics position peaked at $656K in Q4 2020.
  • 473 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2021.

Based on RFG Advisory's 13F filing for Q3 2021, filed 19 Oct 2021.